HepG2 Transfection Kit (Hepatocellular Carcinoma)

$236.00$1,473.00

Kit Size VolumePriceAdd to Cart
0.5 ml (Catalog #2067)$236.00
1.5 ml (Catalog #2068)$491.00
1.5 ml CRISPR (Catalog #2154)$691.00
8.0 ml (Catalog #2069)$1,473.00
SKU: HEPG2

Description

NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.

Transfection Reagent for HepG2 Cells (Hepatocellular Carcinoma Cells, HB-8065)

  • Proprietary cationic lipids formulation
  • High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
  • Effective and robust intracellular delivery
  • Kit includes Transfection Enhancer reagent
  • Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
  • Work in the presence of serum
  • A proven reagent for establishing stable cell lines
  • Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
  • Download in vitro HepG2 transfection protocol: [PDF]
  • Download PowerPoint presentation for HepG2 cells transfection kit: [PPT]
  • Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems HepG2 Transfection Protocol: [PDF]

Download MSDS: [PDF]

HepG2 Cell Line:

HepG2 was derived from the liver tissue of a 15 year-old male with differentiated hepatocellular carcinoma. These cells are epithelial and have model chromosome number of 55. The cells secrete a variety of major plasma proteins such as albumin, transferrin, alpha 1-antitrypsin, alpha 2-macroglobulin, and plasminogen (they have been grown successfully in large scale cultivation systems). The cells are responsive to stimulation with human growth hormone. HepG2 cells have also been shown to be resistant to G418. HepG2 cells and its derivatives are used as a model system for studies of liver metabolism and toxicity of xenobiotics, anti genotoxic and cogenotoxic agents, understanding hepatocarcinogenesis, the detection of cytoprotective, and for drug targeting studies. HepG2 cells are also employed in trials with bio-artificial liver devices. This cell line is widely used in human cancer research of the liver, and could be useful for many different types of biomedical research. HepG2 cells produce albumin, transferrin, fibrinogen, plasminogen, and respond to human growth hormone (hGH).

Data:

Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the HepG2 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=3).

HepG2-cells-transfection-protocol

Figure 2. Protein expression of GAPDH in HepG2 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into HepG2 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected HepG2 transfection reagent product citations:

  • Journal of Molecular Endocrinology 2010. Identification of protein kinases that control ovarian hormone release … Sirotkin et al [PDF]
  • FEBS Letters 2009 (583). MicroRNA 125a and its regulation of the p53 tumor suppressor gene … Zhang et al [PDF]
  • Cellular Physiology 2011. Identification of MicroRNAs Controlling Human Ovarian Cell Proliferation … Sirotkin et al [PDF]

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
  • Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
  • Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
  • 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
  • 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]
  • British Journal of Cancer. 2012 107(3):516-26. TIGAR induces p53-mediated cell-cycle … Madan et al [PDF]
  • 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
  • Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
  • 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]
  • Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]
  • PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
  • J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
  • 2011 141(2) Differential type I interferon-mediated autophagic trafficking … Desai et al [PDF]
  • PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]

Altogen Biosystems:

Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #2067)
  • 1.5 ml (Catalog #2068)
  • 1.5 ml CRISPR (Catalog #2154)
  • 8.0 ml (Catalog #2069)

Additional information

Kit Size (Volume)

0.5 ml (Catalog #2067), 1.5 ml (Catalog #2068), 1.5 ml CRISPR (Catalog #2154), 8.0 ml (Catalog #2069)